HCPCS Level II code C2623 represents a drug-coated, non-laser transluminal angioplasty catheter used in endovascular procedures to dilate stenotic vessels while locally delivering a therapeutic agent. This device-level code matters nationally because drug-coated angioplasty catheters are an important option in peripheral and possibly coronary interventions where reducing restenosis risk is a clinical goal. Payer coverage and reimbursement policies for device codes such as C2623 affect access to these technologies and the economics of interventional vascular care.

Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, sites of service, and typical use cases for the device. The publication also presents benchmarking and coverage themes, notes on where policy updates have recently influenced device utilization, and guidance on common modifier and billing considerations where available.

This national-level summary is designed to inform health policy analysts, billing professionals, and clinical administrative teams about the coding identity and clinical role of C2623, highlight payer relevance, and outline the types of operational and policy insights included in the full publication. Data not available in the input will be indicated within specific sections of the report.